Faculty : Steven Horwitz, MD. Associate Attending
Memorial Sloan Kettering Cancer Center, New York, NY
Last Modified: May 3, 2013
Non-Hodgkin's lymphoma (NHL) is the most common hematologic malignancy in adults, and the sixth most common cancer diagnosed in the United States each year. Upon completion of this activity, participants will be able to: 1)Review recent revisions to NHL treatment guidelines, including updated therapy algorithms, 2) Review the complications associated with treating patients with NHL, and 3) Review the most current data about new therapies, treatment strategies, and combination regimens for NHL.
Sep 26, 2012 - An initial watch-and-wait strategy does not have a detrimental effect on the freedom from treatment failure or overall survival rate in selected patients with low-tumor burden follicular lymphoma compared with patients initially treated with rituximab-containing regimens, according to research published online Sept. 24 in the Journal of Clinical Oncology.
Mar 13, 2014
Nov 11, 2010